Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials.

この研究はインパクトが大きい可能性があると判断されました。 OEのAIによるハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文の影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することができ、読者は将来の診療を形成する可能性が最も高い論文に焦点を当てることができます。

研究概要

1073 patients experiencing moderate-to-severe acute pain following bunionectomy were randomized to receive oral suzetrigine, hydrocodone bitartrate–acetaminophen, or placebo. The primary outcome of interest was the time-weighted sum of pain-intensity differences over 48 hours (SPID48), measured using the Numeric Pain Rating Scale (NPRS). Secondary outcomes included SPID48 compared with hydrocodone–acetaminophen, time to clinically meaningful pain relief, and adverse events. Outcomes were assessed over 48 hours. Overall, the results revealed that suzetrigine significantly reduced postoperative pain compared with placebo but did not demonstrate superiority over hydrocodone–acetaminophen. Suzetrigine was generally well tolerated, with fewer gastrointestinal adverse events than hydrocodone–acetaminophen. These findings suggested that suzetrigine could provide an effective nonopioid alternative for managing moderate-to-severe acute postoperative pain.